Bimekizumab efficacy using IHS4 outcomes in hidradenitis suppurativa: Results from BE HEARD I and II - PubMed
7 days ago
- #hidradenitis suppurativa
- #bimekizumab
- #IHS4
- Bimekizumab efficacy was evaluated using IHS4 outcomes in patients with moderate to severe hidradenitis suppurativa (HS) in the BE HEARD I and II Phase 3 studies.
- Patients received different dosing regimens of bimekizumab (320 mg every 2 weeks or every 4 weeks) or placebo, with assessments up to Week 48.
- At Week 16, bimekizumab-treated patients showed greater reductions in IHS4 scores compared to placebo, with improvements sustained through Week 48.
- The proportion of patients with severe HS decreased by approximately 50% by Week 48 across all treatment arms.
- About 23.7% to 26.7% of patients achieved an IHS4 score of 0 (no abscesses, inflammatory nodules, or draining tunnels) by Week 48.
- Bimekizumab demonstrated significant efficacy in reducing lesion counts and improving HS severity as measured by IHS4.